Fujifilm Holdings Corp · TSE:4901
Fujifilm — Q3 FY2025 Earnings Presentation
34 slides from Fujifilm's earnings presentation, Feb 5, 2026
Slide 1: Earnings Presentation: Financial Results for Q3 FY2025
Earnings Presentation Financial Results for Q3 FY2025 February 5, 2026 FUJIFILM Holdings Corporation Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are m anagement’s current assumptions and beliefs based on currently availab
Slide 2: Agenda
Agenda Consolidated Financial Results for Q3 FY2025 (October to December 2025) Earnings Highlights 1 Teiichi Goto, President, Representative Director & CEO FUJIFILM Holdings Corporation Financial Results and Business Summary by Operating Segment 2 Masayuki Higuchi, Director & Corporate Vice Presiden
Slide 3: Q3 FY2025 Earnings Highlights
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 Earnings Highlights 01 FUJIFILM Holdings Corporation 3
Slide 4: Consolidated Performance for Q3 FY2025
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Earnings Highlights for Q3 FY2025 (Exchange rates: ¥154/US$ | +¥2 YoY; ¥179/Euro | +¥16 YoY) Consolidated Performance for Q3 FY2025 Revenue Operating income Net income attributable to FUJIFILM Holdings Record high Record high Record high ¥ 857
Slide 5: Full-year Consolidated Forecast for FY2025
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Earnings Highlights for Q3 FY2025 Full-year Consolidated Forecast for FY2025 (Exchange rates: Q4 ¥155/US$; ¥175/Euro / Full year ¥150/US$; ¥173/Euro) Net income Revenue Operating income attributable to FUJIFILM Holdings Record high Record high
Slide 6: Q3 FY2025 Financial Results and Business Summary by Operating Segment
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 Financial Results and Business Summary by Operating Segment 02 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies with fi
Slide 7: Financial Results for Q3 FY2025
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Financial Results for Q3 FY2025 (Billions of yen) Q3 9months FY2024 FY2025 Change Impact of Constant- FY2024 FY2025 Change Impact of Constant- exchange rate currency basis exchange rate currency basis Revenue 812.8 Record high 857.4 44.6 16.9
Slide 8: Consolidated Revenue and Operating Income by Operating Segment
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 Consolidated Revenue and Operating Income by Operating Segment (Billions of yen) Q3 9months Revenue FY2024 FY2025 Change FY2024 FY2025 Change Constant-currency basis Constant-currency basis * Healthcare 247.1 266.1 19.1 +7.7% 11.8 +4
Slide 9: Business Summary: Healthcare
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 (October to December 2025) Business Summary: Healthcare Revenue and income （Billions of yen） Factors affecting revenue FY2024 FY2025 Change ◼ Medical Systems Constant- currency basis + Strong sales of endoscopes, medical IT, IVD, etc
Slide 10: Business Summary: Electronics
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 (October to December 2025) Business Summary: Electronics Revenue and income （Billions of yen） Factors affecting revenue ◼ Semiconductor Materials FY2024 FY2025 Change Constant- + Strong sales of materials for advanced nodes, includin
Slide 11: Business Summary: Business Innovation
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 (October to December 2025) Business Summary: Business Innovation Revenue and income （Billions of yen） Factors affecting revenue FY2024 FY2025 Change Constant- ◼ Business Solutions (BS) currency basis + Strong sales of DX solutions Re
Slide 12: Business Summary: Imaging
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 (October to December 2025) Business Summary: Imaging Revenue and income （Billions of yen） Factors affecting revenue ◼ Consumer Imaging FY2024 FY2025 Change Constant- currency basis + Strong sales of instax instant photo systems • Str
Slide 13: Consolidated Cash Flow
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 (April to December 2025) Consolidated Cash Flow Cash in Cash out (Billions of yen) Adjusted free cash flow excluding business acquisitions FY2023 FY2024 FY2025 9months 9months 9months (Billions of yen) Net income 173.0 182.2 193.8 31
Slide 14: Financial Forecast for FY2025
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Financial Forecast for FY2025 03 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100million. As a result, there may be some discrepancies from figures published in the past, and in some
Slide 15: Full-year Forecast for FY2025
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Full-year Forecast for FY2025 Operating income and net income attributable to FUJIFILM Holdings revised upward from previous forecast (Nov. 6) (Billions of yen) FY2025 FY2025 FY2024 Change from Change from Previous forecast Revised forecast Ac
Slide 16: Financial Forecast by Operating Segment
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Financial Forecast by Operating Segment Operating income has been revised upward, driven by strong sales in Electronics and Imaging, despite downward revisions in both Healthcare and Business Innovation to reflect expenses for strengthening th
Slide 17: Bio CDMO Business: FY2025 Financial Forecast and FY2026 Financial Outlook
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Bio CDMO Business: FY2025 Financial Forecast and FY2026 Financial Outlook FY2025 While the launch of new large-scale facilities is progressing, we anticipate impacts on small- to medium-scale facilities due to delays in securing early-stage pr
Slide 18: Impact of the U.S. Tariff Policy
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Impact of the U.S. Tariff Policy Forecast impact of the U.S. tariff policy is unchanged from previous forecast Assumptions Based on information announced by the U.S. government as of February 1, Japan time. Reciprocal tariffs agreed upon or ap
Slide 19: Appendices: Financial Results for Q3 FY2025
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Appendices: Financial Results for Q3 FY2025 04 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100million. As a result, there may be some discrepancies from figures published in the past
Slide 20: 3Q | 9 Months Earnings
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices 3Q | 9 Months Earnings (Billions of yen) Q3 9months Revenue FY2025 FY2025 FY2024 Change Constant-currency basis FY2024 Change Constant-currency basis Healthcare 247.1 266.1 19.1 +7.7% 11.8 +4.8% 731.3 765.3 34.0 +4.7% 36.2 +5.0% * Medical Syst
Slide 21: Quarterly Earnings
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Quarterly Earnings FY2024 FY2025 Revenue Q1 Q2 Q3 Q4 Q1 Q2 Q3 * Healthcare 235.2 249.0 247.1 316.5 228.5 270.7 266.1 Medical Systems 157.7 166.9 162.6 206.1 144.0 170.3 170.2 Bio CDMO 47.1 48.1 51.3 73.0 53.2 66.3 60.8 LS Solutions 30.4 34.1 3
Slide 22: Consolidated Revenue by Geographical Area
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Consolidated Revenue by Geographical Area (Billions of yen) FY2024 9months FY2025 9months Change Ratio (%) Ratio (%) Japan 32.9% 765.6 34.0% 825.9 60.3 +7.9% The Americas 20.9% 487.2 20.0% 486.0 (1.2) (0.2%) Europe 16.9% 392.2 17.6% 427.1 34.9
Slide 23: Operating Income Analysis (Q3 YoY)
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Operating Income Analysis (Q3 YoY) (Billions of yen) Q3 (a) (b) FY2024 FY2025 Operation Raw Material Tariff （b-a) Change FX FY2024 FY2025 Business Detail Actual Actual and others price Impact One-time cost Q3 Q3 * Healthcare 11.4 10.3 (1.2) 1.
Slide 24: Full-year Forecast for FY2025: Revenue by Business
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Full-year Forecast for FY2025 Revenue by Business (Billions of yen) FY2024 FY2025 FY2025 Change from Change from Actual Previous forecast Revised forecast previous year previous forecast (as of Nov. 6, 2025) (as of Feb. 5, 2026) * Healthcare 1
Slide 25: Operating Income Analysis (FY2025 Forecast vs. Previous Forecast)
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Operating Income Analysis (FY2025 Forecast vs. Previous Forecast) (Billions of yen) Previous Revised (a) (b) forecast forecast Operation Raw Material （b-a) Change FX tariff Previous Revised Business Detail (Nov.6,2025) (Feb.5,2026) and others
Slide 26: Operating Income Analysis (FY2025 Forecast vs. Previous Forecast)
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Operating Income Analysis (FY2025 Forecast vs. Previous Forecast) (Billions of yen) Previous Revised (a) (b) forecast forecast Operation Raw Material （b-a) Change FX tariff Previous Revised Business Detail (Nov.6,2025) (Feb.5,2026) and others
Slide 27: Bio CDMO Profitability (Q3 YoY; FY2025 Forecast YoY)
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Bio CDMO Profitability (Q3 YoY; FY2025 Forecast YoY) （Billions of yen) Q3 Full Year vs Previous FY2025 FY2025 vs Previous Bio CDMO Year Year FY2024 FY2025 FY2024 (Previsus Forecast (Revised Forecast as of Nov.6, 2025) as of Feb.5,2026) Revenue
Slide 28: Consolidated Balance Sheets
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Q3 FY2025 Consolidated Balance Sheets (Billions of yen) Change from Change from Mar. 2024 Mar. 2025 Dec. 2025 Mar. 2024 Mar. 2025 Dec. 2025 Mar. 2025 Mar. 2025 Cash and cash equivalents 179.7 172.1 188.1 16.0 Short-term and long-term debt 502.
Slide 29: Capital Expenditure and Depreciation & Amortization
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Capital Expenditure and Depreciation & Amortization (Billions of yen) Capital Expenditure and Depreciation & Amortization (Billions of yen) (億円) Q3 9months Full Year 600.0 6,000 FY2025 FY2024 FY2025 FY2024 FY2025 FY2024 532.1 Forecast * Health
Slide 30: R&D Expenses and SG&A Expenses
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices R&D Expenses and SG&A Expenses R&D Expenses and SG&A Expenses Ratio to revenue (Billions of yen) (Ratio to revenue) (Billions of yen) 9,000 40.0% 900.0 806.5 Q3 9months Full Year 752.5 FY2025 FY2024 FY2025 FY2024 FY2025 FY2024 30.0% Forecast 6
Slide 31: Market Trend and Number of Employees
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices Market Trend and Number of Employees ▐ Exchange rates (average) / Raw material prices (average) FY2024 FY2025 Unit Q1 Q2 Q3 Q4 Full Year Q1 Q2 Q3 9months Q4 Full Year US$ ¥/€ 156 149 152 152 152 145 148 154 149 155 150 € ¥/€ 168 164 163 161 16
Slide 32: References
Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices References ▍ FUJIFILM Holdings - Investor Relations https://ir.fujifilm.com/en/investors.html ▍ FUJIFILM Holdings Integrated Report https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html ▍ IR Materials https://ir.fujifilm.com
Slide 33: FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation
Slide 34: FUJIFILM
FUJIFILM Value from Inn